Hayashi Toshiyuki, Fukui Tomoyasu, Nakanishi Noriko, Yamamoto Saki, Tomoyasu Masako, Osamura Anna, Ohara Makoto, Yamamoto Takeshi, Ito Yasuki, Hirano Tsutomu
Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa University School of Medicine, 1-5-8, Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan.
Reagent R&D Department, Denka Seiken Co., Ltd., Nihonbashi Mitsui Tower, 1-1, Nihonbashi-Muromachi 2-chome, Chuo-ku, Tokyo, 103-8338, Japan.
Cardiovasc Diabetol. 2017 Nov 13;16(1):149. doi: 10.1186/s12933-017-0608-5.
Following publication of the original article [1], the authors identified a number of errors. In Result (P.3), Table 1 (P.4), Table 5 (P.9) and Supplementary Table 1, the correct unit for adiponectin was μg/mL. In Table 1 (P.4), the correct value for the post treatment body weight in dapagliflozin was 76.2±14.8. In Table 6 (P.10), the correct value for the pre treatment sd LDL/LDL-C in decreased LDL-C group was 0.38±0.10.
在原文章[1]发表后，作者发现了一些错误。在结果部分（第3页）、表1（第4页）、表5（第9页）和补充表1中，脂联素的正确单位是μg/mL。在表1（第4页）中，达格列净治疗后体重的正确值是76.2±14.8。在表6（第10页）中，低密度脂蛋白降低组治疗前sd LDL/LDL-C的正确值是0.38±0.10。
